Skip to main content
. 2021 Jul 22;27(19):5258–5271. doi: 10.1158/1078-0432.CCR-21-0273

Table 2.

Baseline patient and disease characteristics by baseline EGFR-activating mutation subgroup and by treatment arms.

Total Ex19del Ex21L858R
Ex19del (N = 243) Ex21L858R (N = 204) RAM+ERL (N = 123) PBO+ERL (N = 120) RAM+ERL (N = 99) PBO+ERL (N = 105)
Sex, n (%) Female 146 (60) 136 (67) 74 (60) 72 (60) 66 (67) 70 (67)
Age in years, median (range) 63 (23–84) 66 (41–89) 64 (27–84) 63 (23–83) 67 (44–86) 66 (41–89)
Racea Asian 174 (72) 170 (83) 89 (72) 85 (71) 81 (82) 89 (85)
Caucasian 67 (28) 33 (16) 34 (28) 33 (28) 18 (18) 15 (14)
Smoking history, n (%) Never 144 (59) 127 (62) 71 (58) 73 (61) 61 (62) 66 (63)
ECOG performance status, n (%) 0 131 (54) 103 (51) 65 (53) 66 (55) 50 (51) 53 (51)
Disease classification, n (%) Primary metastatic 207 (85) 178 (87) 103 (84) 104 (87) 91 (92) 87 (83)
Recurrent metastatic 36 (15) 26 (13) 20 (16) 16 (13) 8 (8) 18 (17)
Metastases sites, n (%) Lung 224 (92) 188 (92) 112 (91) 112 (93) 93 (94) 95 (91)
Lymph 152 (63) 127 (62) 78 (63) 74 (62) 64 (65) 63 (60)
Bone 63 (26) 69 (34) 35 (29) 28 (23) 33 (33) 36 (34)
Liver 26 (11) 19 (9) 11 (9) 15 (13) 10 (10) 9 (9)
Other 146 (60) 104 (51) 70 (57) 76 (63) 48 (49) 56 (53)
Number of metastatic sites 1 29 (12) 23 (11) 12 (10) 17 (14) 9 (9) 14 (13)
2 90 (37) 86 (42) 50 (41) 40 (33) 46 (47) 40 (38)
3 99 (41) 74 (36) 50 (41) 49 (41) 32 (32) 42 (40)
4 20 (8) 15 (7) 11 (9) 9 (8) 9 (9) 6 (6)
≥5 5 (2) 6 (3) 0 5 (4) 3 (3) 3 (3)

Abbreviations: ECOG, Eastern Cooperative Oncology Group; n, number of patients per category; N, number of patients in population.

aPBO + ERL arm included three Other: one Black or African American, one Missing (ex19del group), one American Indian or Alaska Native (ex21L858R group).